
|Articles|September 12, 2017
Tufts Finds Cardiovascular Drug Approval Rate in the US Fell
Advertisement
Tufts Center for the Study of Drug Development recently completed a study, which was released September 12. The findings show that even though the rate at which investigational drugs received marketing approval in the U.S. has declined in recent years, the cardiovascular approval rate trailed other drug approvals, while the time needed to develop cardiovascular drugs rose.
Read the full release
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
ACT Brief: Real-Time Evidence Generation, Protocol Digitization, and Decentralized Trial Flexibility
2
Achieving Clinical Trial Success with Three Key Elements of eCOA User Acceptance Testing
3
Tapping the Global Potential of China’s Biotech Surge
4
2026 DIA Global Annual Meeting: How Structured Protocols Enable Automated Amendments and Real-Time FDA Oversight
5




